Crossref
Targeting the Lectin Pathway in Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy: Narsoplimab Enters the Arena
The Hematologist · 01.05.2026 · 23 (3)
DOI: 10.1182/hem.v23.3.202633 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Hematologist, online erschienen am 17.04.2026. Verfasst von Meera Sridharan. Die Arbeit nennt 11 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Sridharan, M. (2026). Targeting the Lectin Pathway in Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy: Narsoplimab Enters the Arena. The Hematologist, 23(3). https://doi.org/10.1182/hem.v23.3.202633
Vancouver
Sridharan M. Targeting the Lectin Pathway in Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy: Narsoplimab Enters the Arena. The Hematologist. 2026;23(3). doi:10.1182/hem.v23.3.202633
BibTeX
@article{Sridharan2026,
author = {Sridharan, Meera},
title = {Targeting the Lectin Pathway in Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy: Narsoplimab Enters the Arena},
journal = {The Hematologist},
year = {2026},
volume = {23},
number = {3},
doi = {10.1182/hem.v23.3.202633}
}
EUVIMED